Your session is about to expire
← Back to Search
Pepinemab for Alzheimer's Disease (SIGNAL-AD Trial)
SIGNAL-AD Trial Summary
This trial is testing a new drug for Alzheimer's disease to see if it is safe, tolerated, and effective.
SIGNAL-AD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSIGNAL-AD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SIGNAL-AD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am a woman who cannot become pregnant.I have been diagnosed with a neurological condition that affects my thinking.I have someone close who can attend all trial visits with me.I have had cancer within the last 2 years.I am currently dealing with a serious infection.I meet specific health and cognitive function criteria.I do not have any major health issues unrelated to my current condition.I agree to use birth control during and for 6 months after the study.I am receiving an FDA-approved treatment for Alzheimer's.I am between 55 and 85 years old.I have a significant blood, liver, heart, or kidney condition.Your MMSE score is between 17 and 26.
- Group 1: Placebo
- Group 2: pepinemab 40mg/kg
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many facilities are currently overseeing this research?
"The trial is presently running in 14 different sites, such as Premiere Research Institute of Palm Beach, Neurology in Palm Beach and Albany's Neurological Associates. Dent Neurological Associates also has a presence at Amherst alongside the other participating medical centres."
Am I eligible to be involved in this research initiative?
"Patients with Alzheimer's disease, aged 55 to 85, are eligible for this medical trial which seeks a total of 40 participants."
Have there been other investigations with regard to the efficacy of Pepinemab?
"Currently, 6 separate trials are being conducted to research the efficacy of Pepinemab. None of these studies have advanced to Phase 3 yet. While most investigations center in Saint Louis, Missouri, there exist 61 distinct clinical sites studying this medication."
Are recruitment efforts still ongoing for this trial?
"According to the clinicaltrials.gov website, this medical trial is presently looking for volunteers. The initial posting of the study was on July 22nd 2021 and it has since been revised as recently as October 6th 2022."
What is the current count of participants for this medical experiment?
"The medical trial necessitates the enrollment of 40 eligible patients, who can join either at Premiere Research Institute in Palm Beach or Neurological Associates in Albany."
Is this clinical trial restricted to those under the age of 75?
"As stipulated in the inclusion criteria, potential participants of this clinical trial must be between 55 and 85 years old. Currently there are 24 studies involving patients under 18 and 541 trials with elderly individuals as their primary cohort."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger